Still, insulin-resistant and insulin-deficient rats benefit from oral CAPE administration (30 mg/kg/day) as it ameliorates the rise in blood pressure, an effect attributed to CAPE-mediated improvement of vascular reactivity and stiffness (Hassan et al., 2014). The gene discussed is INS; the disease is Insulin resistance.